1. Home
  2. ALXO vs CREX Comparison

ALXO vs CREX Comparison

Compare ALXO & CREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALXO
  • CREX
  • Stock Information
  • Founded
  • ALXO 2015
  • CREX N/A
  • Country
  • ALXO United States
  • CREX United States
  • Employees
  • ALXO N/A
  • CREX N/A
  • Industry
  • ALXO Biotechnology: Pharmaceutical Preparations
  • CREX EDP Services
  • Sector
  • ALXO Health Care
  • CREX Technology
  • Exchange
  • ALXO Nasdaq
  • CREX Nasdaq
  • Market Cap
  • ALXO 24.0M
  • CREX 33.5M
  • IPO Year
  • ALXO 2020
  • CREX N/A
  • Fundamental
  • Price
  • ALXO $0.56
  • CREX $3.05
  • Analyst Decision
  • ALXO Strong Buy
  • CREX Strong Buy
  • Analyst Count
  • ALXO 6
  • CREX 2
  • Target Price
  • ALXO $3.30
  • CREX $8.00
  • AVG Volume (30 Days)
  • ALXO 456.6K
  • CREX 163.1K
  • Earning Date
  • ALXO 05-08-2025
  • CREX 05-14-2025
  • Dividend Yield
  • ALXO N/A
  • CREX N/A
  • EPS Growth
  • ALXO N/A
  • CREX N/A
  • EPS
  • ALXO N/A
  • CREX N/A
  • Revenue
  • ALXO N/A
  • CREX $48,303,000.00
  • Revenue This Year
  • ALXO N/A
  • CREX $10.05
  • Revenue Next Year
  • ALXO N/A
  • CREX $18.73
  • P/E Ratio
  • ALXO N/A
  • CREX N/A
  • Revenue Growth
  • ALXO N/A
  • CREX 1.68
  • 52 Week Low
  • ALXO $0.41
  • CREX $1.28
  • 52 Week High
  • ALXO $10.97
  • CREX $5.20
  • Technical
  • Relative Strength Index (RSI)
  • ALXO 59.08
  • CREX 67.40
  • Support Level
  • ALXO $0.44
  • CREX $2.75
  • Resistance Level
  • ALXO $0.48
  • CREX $3.89
  • Average True Range (ATR)
  • ALXO 0.05
  • CREX 0.41
  • MACD
  • ALXO 0.02
  • CREX 0.10
  • Stochastic Oscillator
  • ALXO 99.16
  • CREX 62.33

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About CREX Creative Realities Inc.

Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The Company operates in one reportable segment, marketing technology solutions. The company provides solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media.

Share on Social Networks: